Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report sent to investors on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Up 11.6 %

Galmed Pharmaceuticals stock opened at $3.37 on Friday. The business has a 50 day moving average price of $3.58 and a two-hundred day moving average price of $4.08. Galmed Pharmaceuticals has a 12 month low of $2.73 and a 12 month high of $10.50. The stock has a market cap of $1.79 million, a price-to-earnings ratio of -1.40 and a beta of 0.67.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.